Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening

Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used....

Descripción completa

Detalles Bibliográficos
Autores principales: Laios, Alexandros, Mohamed, Bashir M., Kelly, Lynne, Flavin, Richard, Finn, Stephen, McEvoy, Lynda, Gallagher, Michael, Martin, Cara, Sheils, Orla, Ring, Martina, Davies, Anthony, Lawson, Margaret, Gleeson, Noreen, D’Arcy, Tom, d’Adhemar, Charles, Norris, Lucy, Langhe, Ream, Saadeh, Feras Abu, O’Leary, John J., O’Toole, Sharon A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565367/
https://www.ncbi.nlm.nih.gov/pubmed/23340649
http://dx.doi.org/10.3390/ijms14012085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565367/
https://www.ncbi.nlm.nih.gov/pubmed/23340649
http://dx.doi.org/10.3390/ijms14012085

Ejemplares similares